Your Guide to NFCR-supported Researchers Featured at ASCO 2025
Several NFCR-supported researchers will showcase their work at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, over the coming days.
Widely recognized as one of the most prominent gatherings in the oncology community, ASCO’s Annual Meeting highlights work that is shaping the future of cancer research.
The theme for this year’s ASCO Annual Meeting (2025) is Driving Knowledge to Action: Building a Better Future.
What does that mean for cancer patients? It may be a great comfort to some cancer patients to know that our community is actively working on solutions that make their survivorship possible. By bringing together leaders working across all types of cancer research, there is hope for advancing our overall understanding of how to prevent, detect, and treat cancer more effectively.
The strong presence of NFCR-funded researchers at this year’s conference underscores our ongoing commitment to advancing cancer research and honors the vital support of our donors. Their work represents meaningful progress on the path to curing cancer and exemplifies the impact of investing in innovative science.
NFCR-supported researchers whose work is being featured include (in no particular order):
- Massimo Cristofanilli
- Azra Raza
- Aaron Hata
- Jessica Lin
- Paul Nghiem
- Silvio Gutkind
- Kornelia Polyak
- Suzanne Topalian
- Ritesh Kotecha
- Elana Fertig
- Christian Rolfo
- Aditya Bardia
- Himisha Beltran
Note: This piece is still developing, and we will continue to make updates as the meeting goes on!
More Details on NFCR Research Programs at ASCO 2025:
Himisha Beltran is participating in an educational session about personalizing treatments for patients with metastatic castrate-resistant prostate cancers. Specifically, Dr. Beltran will share her expert insights on Non–Androgen Receptor–Driven Prostate Cancers.
Prostate cancer is the second most commonly diagnosed cancer in the US and the second leading cause of cancer-related deaths in American men. Dr. Beltran’s NFCR-supported work is focused on finding more non-invasive ways to detect subtypes of prostate cancer in order to develop more effective treatments.
Additionally, she will have several other findings featured in the poster sessions.
Also, an update on GBM AGILE will be given at ASCO 2025 from the Global Coalition for Adaptive Research (GCAR) team.
GBM AGILE is a revolutionary clinical trial platform designed for patients battling the deadliest brain cancer, glioblastoma, for which NFCR and CEO Dr. Sujuan Ba played a pivotal role in helping launch. To date, GBM AGILE has screened over 2,300 patients, and enrollment continues to be robust. An estimated 25% of all US glioblastoma patients enrolled in clinical trials participate in GBM AGILE. The trial is open at select sites in the United States, Canada, Switzerland, France, Germany, and Australia (View More).
Part of Dr. Ba’s vision for the future of GBM AGILE is to see it expand to treat other difficult and deadly cancers. NFCR supporters can take great pride in the growth of this initiative for our early impact that helped make this growth possible!
You can find additional details on the work being shared at ASCO 2025 on their event website >>>
Continuing the Conversation at NFCR’s 2025 Global Summit
Save the Date: October 24, 2025 – Washington, D.C.
Join us for the 2025 NFCR Global Summit, where influential voices in cancer research, including several NFCR-supported scientists and other world leaders, will come together to discuss the future of oncology. This prestigious event will feature dynamic conversations on advancing cancer research and fostering collaboration to improve outcomes for patients worldwide.
Stay tuned! Throughout the summer, we will unveil more details about the program and announce this year’s award recipients. Early bird registration is now open, and space is limited. With high interest anticipated following the announcement of our honorees, we encourage you to secure your spot today.
NFCR is dedicated to curing ALL cancers by supporting excellence in cancer research.
By emphasizing “high-risk, high-impact” long-term and transformative pioneering research fields often overlooked by other major funding sources, NFCR also supports research leaders across all cancer areas. We believe that research is the key to breakthroughs and the possibility of saving more lives. Visit Our Scientists to learn more about our scientists and their work.
Become a part of this journey today, and let’s make cures possible! Learn how you can support our mission!
